InflaRx Engages with Investors at Key Upcoming Conferences
InflaRx N.V. Welcomes Investor Engagement in Upcoming Summits
InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company based in Germany, is gearing up to take part in several noteworthy investor conferences this summer. As a trailblazer in developing innovative therapeutics aimed at combating inflammation by targeting the complement system, InflaRx is poised to showcase its advancements and connect with potential investors.
Jeffries Global Healthcare Conference
The company is set to participate in the prestigious Jefferies Global Healthcare Conference happening shortly. This event will occur from June 3rd to June 5th. As part of this gathering, InflaRx will host an investor presentation on June 4th at 7:35 AM ET. The presentation aims to share insights into the company’s strategic direction and innovations in the biopharmaceutical landscape. After the presentation, there will be opportunities for one-on-one investor meetings, highlighting InflaRx's commitment to fostering direct relationships with its investors.
Oppenheimer Innovators in I&I Summit
Continuing its proactive engagement with the investment community, InflaRx will also appear at the Oppenheimer Innovators in Inflammation and Immunology Summit. Scheduled for June 25th, this summit will feature InflaRx on a panel discussing recent advancements in dermatology, specifically focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). This panel is expected to take place from 10:45 to 11:20 AM ET, providing a platform for InflaRx to demonstrate its pivotal role in developing solutions for these challenging conditions.
Leerink Partners Therapeutics Forum
Another significant event on InflaRx’s calendar is the Leerink Partners Therapeutics Forum, which focuses on inflammation and metabolism. This event is set for July 8th and 9th. In addition to networking with other industry leaders, the company will participate in individual meetings with investors on July 8th. Both events are created to foster deep discussions and engagement with potential stakeholders, allowing InflaRx to present its cutting-edge product pipeline.
About InflaRx N.V.
InflaRx N.V. is at the forefront of biopharmaceutical innovation with a focus on anti-inflammatory therapies. Utilizing its proprietary technologies, the company is dedicated to developing targeted treatments that address the complement activation factor C5a and its receptor, C5aR. This area of research is crucial, as C5a is recognized as a significant factor in the progression of various inflammatory diseases.
The company’s flagship product, vilobelimab, stands out as a first-in-class, intravenously administered monoclonal antibody. This innovative treatment selectively binds to the free C5a protein and has shown promising disease-modifying capabilities along with a favorable safety profile in numerous clinical trials. Furthermore, InflaRx is advancing its small molecule treatment, INF904, which offers a novel oral administration option for patients.
Founded in 2007, InflaRx N.V. maintains offices in both Germany and the United States, solidifying its international presence and dedication to enhancing patient health worldwide. For those eager to learn more about InflaRx and its initiatives, more information is available through their official resources.
Contact Information
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is InflaRx N.V. known for?
InflaRx N.V. specializes in developing innovative anti-inflammatory therapies targeting the complement system.
When will InflaRx present at the investor conferences?
InflaRx will present on June 4th at the Jefferies Global Healthcare Conference and participate in various meetings.
What is vilobelimab?
Vilobelimab is InflaRx's lead product candidate, an intravenous monoclonal antibody targeting free C5a to treat inflammatory diseases.
Where are InflaRx’s offices located?
InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.
How can I get in touch with InflaRx?
Interested parties can contact InflaRx through their investor relations email or the provided contact details for further inquiries.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.